SGP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.48%, SMA50 0.48%, SMA200 0.48%). The stock remains hovering near 52-week lows, trading -12.61% below its high and over 40.63% above its low. Average 10-day trading volume of 52.23 thousand shares is below the 3-month average of 96.61 thousand, indicating normal recent market interest.

SpyGlass Pharma, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.84. This means the shares are trading above this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $37.00. The high target offers 230.14% upside. The low target suggests 97.02% downside. The mean target is $45.00. This offers 139.62% upside. SpyGlass Pharma, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 2.99%. The prior quarter beat by 896.13%. Over the last six quarters, Apple has recorded several small beats. These include 896.13% in March 26, 2026.

SpyGlass Pharma, Inc. Common Stock (NASDAQ:SGP) closed at $18.78 USD, losing -$0.69 (-3.54%) from the previous close of $19.47. The stock is currently mid-range between its 52-week high and low $17.60 and $32.44. With a market capitalization of about $627.88 million, SpyGlass Pharma, Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~-0.34). Key stats such as the average daily volume over the past year has been around 95.21 thousand shares, in line with its 52-week average. Headquartered in Aliso Viejo, CA, SpyGlass Pharma, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Patrick H. Mooney, the company employs approximately 1,489 people and listed since January 08, 2008. SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions.

Our AI price prediction model suggests that SpyGlass Pharma, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.84%, with price expected at $15.43 by June 19, 2026, within a range of $14.60 to $16.28 3-Month Outlook: Projected fall of -24.6%, reaching $14.16 by September 03, 2026, with a range of $13.95 to $14.40. 1-Year Outlook: Projected gain of 4.26%, with price at $19.58 by June 04, 2027, within a range of $19.39 to $19.85.

currently trading near 52-week highs band. Valuation shows SpyGlass Pharma, Inc. Common Stock trading at a premium to the broader market with a P/E of -14.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.00, suggesting 139.62% upside. Our AI forecast model points to short-term weakness (-17.84% over two weeks), a medium-term fall (-24.6% over three months), and a longer-term gain (4.26% over one year), with expected trading ranges indicating moderate volatility.

SpyGlass Pharma, Inc. Common Stock trades at a P/E ratio of -14.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.5 suggesting the stock is closer to book value. The P/FCF stands at -26.23, also above market averages.